The groundbreaking rise of Viagra has firmly established as a benchmark of pharmaceutical success, but its position within the broader market now triggers questions about potential returns . Alternative versions are eroding patent protection , prompting worries that supporting companies closely tied to Viagra's former position could be a dangerous